News from IMIM
Epigallocatechin gallate (EGCG) – a natural compound found in green tea- could help to improved cognitive development in children, aged 6 to 12, with Down's syndrome. A clinical trial leading by Rafael de la Torre, director of the Neurosciences research programme at the IMIM, is testing the safety and effectiveness of a dietary preparation containing EGCG in a paediatric population with Down's syndrome and, in further steps, will also evaluate its effect on children with Fragile X syndrome.
The paediatric clinical trials will take place simultaneously in five health centres: Hospital Niño Jesús (Madrid), Instituto Hispalense de Pediatria (Seville), Hospital Universitario Marqués de Valdecilla (Santander), Hospital del Mar ( Barcelona), and Institut Jérome Lejeune (Paris), and will involve about 70 children with Down's or Fragile X syndrome. "We are including children with both syndromes because, although their genetic origin is different, the mechanism through which the EGCG could provide therapeutic effects is the same, and for this reason we think that Fragile X sufferers could also benefit", adds Dr. de la Torre. -CS/PRBB